Biosoluble Polymers and Particles for Controlled Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems face challenges such as in vivo instability, immune reactions, complexity in formulation, difficulty in maintaining stability, low drug load, and premature drug release before reaching the target site, particularly for pH and heat-sensitive agents like insulin and vaccines.
Innovation Solution
A method for producing polymers and particles using a carbon donor and metal oxide precursor, with a polycondensation catalyst, forming a scaffold that is covalently connected, allowing for controlled release of active agents like peptides, proteins, and nucleic acids, suitable for oral and mucosal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biosoluble polymers are used for drug delivery, then the active agent is protected until it reaches the target, but the polymers may cause immune reactions and show in vivo instability
Solution Approach 1:
The patent uses composite particles comprising both organic (carbohydrate) and inorganic (metal oxide) components. The inorganic metal oxide shell provides structural stability and reduces immune recognition, while the organic carbohydrate core maintains biosolubility and biodegradability. This composite structure resolves the contradiction by combining materials with complementary properties that simultaneously protect the active agent while minimizing immune reactions.
2Reliability
If complex delivery systems are used to protect active agents, then solubility and bioavailability improve, but formulation complexity increases
Solution Approach 1:
The patent incorporates the active agent into the particle structure during the formation process itself, rather than requiring separate encapsulation steps. The sol-gel methodology allows the active agent to be integrated into the inorganic matrix as the particle forms, simplifying the formulation process while maintaining protection and solubility benefits.
3Duration of action of moving object
If nanoparticles are used for drug delivery, then controlled release at the target site is achieved, but drug load remains low
Solution Approach 1:
The patent utilizes porous inorganic matrices (such as silica-based materials) with controlled pore structures that can accommodate high loads of active agent. The porous structure provides large surface area and volume for drug incorporation while maintaining the nanoparticle size for targeted delivery. The pore size and distribution can be tuned to control release kinetics, thus achieving both high drug load and controlled release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables reliable, controlled delivery of active agents at the target site, reducing degradation and immune reactions, and supports effective vaccination and treatment of metabolic and neurological disorders without causing significant side effects.
Implementation Method 1
adding an alcoholic or hydro-alcoholic solution of a polycondensation catalyst to step a) and/or step b), wherein all the steps are performed at a temperature in a range of about −20° C. to about 55° C., preferably about −5° C. to about 25° C. and the carbon donor and the metal oxide precursor, the metal oxide or a combination thereof form a gel
Implementation Method 2
mixing the saturated solution of step a) with a metal oxide precursor, a metal oxide or a combination thereof, adding an alcoholic or hydro-alcoholic solution of a polycondensation catalyst to step a) and/or step b), wherein all the steps are performed at a temperature in a range of about −20° C. to about 55° C., preferably about −5° C. to about 25° C. and the carbon donor and the metal oxide precursor, the metal oxide or a combination thereof form a gel
Data Source
AI summary
The present invention refers to a method for producing a polymer in form of a gel or a particle, and to the resulting polymer, gel and particle, respectively. The polymer comprises a carbon donor and a metal oxide precursor, a metal oxide or a combination thereof and optionally an active agent. The invention is further directed to a composition and film comprising such polymer, and their use as a medicament for example in treating diabetes, obesity, neuronal disease, viral infection or cancer.